Yoshikazu Takaesu
Overview
Explore the profile of Yoshikazu Takaesu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
717
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hokama N, Ota K, Shiohira H, Takaesu Y, Nakamura K
Int J Clin Pharmacol Ther
. 2025 Mar;
PMID: 40063982
No abstract available.
2.
Krystal A, Blier P, Culpepper L, Nierenberg A, Takaesu Y, Kubota N, et al.
Neuropsychopharmacol Rep
. 2024 Dec;
45(1):e12509.
PMID: 39632341
Aim: Individuals with insomnia frequently have comorbid depression or anxiety. This study sought to provide a preliminary indication of the effects of lemborexant (LEM) in subjects treated for mild depression/anxiety...
3.
Hayasaka T, Nagashima I, Hoshino M, Teruya K, Matumoto Y, Murao M, et al.
PCN Rep
. 2024 Nov;
3(4):e70038.
PMID: 39605926
Aim: Assessing symptoms and daily functioning in patients with major depressive disorder (MDD) can be challenging, as their limited self-monitoring abilities may result in behavior observed during structured interviews not...
4.
5.
Kato T, Ogasawara K, Motomura K, Kato M, Tanaka T, Takaesu Y, et al.
Psychiatry Clin Neurosci
. 2024 Aug;
78(11):633-645.
PMID: 39194164
The Japanese Society of Mood Disorders (JSMD) published treatment guidelines of bipolar disorder in 2011. The present guidelines incorporating new findings were developed to comply to the guidelines of the...
6.
Matsui K, Utsumi T, Aoki Y, Maruki T, Takeshima M, Takaesu Y
J Med Internet Res
. 2024 Aug;
26:e52758.
PMID: 39151163
Background: The screening process for systematic reviews is resource-intensive. Although previous machine learning solutions have reported reductions in workload, they risked excluding relevant papers. Objective: We evaluated the performance of...
7.
Shimura A, Takaesu Y, Sugiura K, Takagi S, Okawa Y, Inoue Y
Sleep Med
. 2024 Aug;
122:99-105.
PMID: 39141977
Objective: Insomnia disorder is a global public health issue, commonly treated with hypnotics. However, long-term use of benzodiazepine derivatives (BZDs), especially polypharmacy with this kind of drug, carries risks for...
8.
Kondo T, Higa R, Kuniba M, Shinzato H, Takaesu Y
Neuropsychopharmacol Rep
. 2024 Jun;
44(3):585-590.
PMID: 38934345
Background: Persistent cognitive impairment is a serious consequence of the post-COVID condition. However, there have been no established effective treatments for this pathophysiology supported by sufficient evidence. Case Presentation: A...
9.
Takeshima M, Sakurai H, Inada K, Aoki Y, Ie K, Kise M, et al.
BMC Prim Care
. 2024 Jun;
25(1):219.
PMID: 38890610
Background: It is unclear how primary care physicians manage insomnia after the introduction of novel hypnotics such as orexin receptor antagonists and melatonin receptor agonists. This Web-based questionnaire survey aimed...
10.
Tsujii N, Okada T, Usami M, Kuwabara H, Fujita J, Negoro H, et al.
PCN Rep
. 2024 Jun;
1(4):e57.
PMID: 38868662
Aim: Current clinical guidelines for attention-deficit/hyperactivity disorder (ADHD) put shared decision making (SDM) at the center of care. However, there remain challenges in SDM in ADHD management, particularly regarding the...